<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>JSLL</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">JSLL</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="jeena-sikho-lifecare-limited" class="section level1">
<h1>Jeena Sikho Lifecare Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JSLL.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-10 </em></p>
<div id="comprehensive-analysis-of-jeena-sikho-lifecare-limited-jsll-bse-scrip-code-544476-nse-symbol-jsll" class="section level9">
<p class="heading"><strong>Comprehensive Analysis of Jeena Sikho Lifecare Limited (JSLL: BSE SCRIP Code 544476, NSE SYMBOL: JSLL)</strong></p>
<p>Based on a detailed review of the unaudited quarterly financial results (September 30, 2025), auditor review reports, disclosures under SEBI Listing Regulations (Regulation 30), internal auditor appointment, and additional notes as of November 2025, the following <strong>strategic synthesis</strong> evaluates the <strong>tailwinds, headwinds, growth prospects, and key risks</strong> for <strong>Jeena Sikho Lifecare Limited (JSLL)</strong>.</p>
<hr />
</div>
<div id="executive-summary" class="section level6">
<h6>üîç <strong>1. Executive Summary</strong></h6>
<p>JSLL is an Ayurvedic healthcare and wellness company transitioning from the SME platform to the Main Board (effective August 2025). It has adopted <strong>Indian Accounting Standards (Ind AS)</strong> with effect from April 1, 2024. This reporting cycle includes its <strong>first consolidated financial statements</strong> after incorporating a new subsidiary, <strong>Jeena Green Resources Private Limited (JGRPL)</strong>, established in March 2025.</p>
<p>For <strong>Q2 FY26 (Sept 2025)</strong>, the company delivered <strong>strong financial performance</strong>, marked by: - Revenue growth: <strong>+66% YoY</strong> in Q2 FY26. - Profit surge: Over <strong>120% YoY growth in PAT</strong>. - Healthy cash flow from operations. - Improved investor visibility with listing on main boards of BSE &amp; NSE.</p>
<p>However, the company is navigating <strong>accounting transition complexities</strong>, <strong>scaling challenges</strong>, and <strong>governance shifts</strong>, which pose early-stage risks.</p>
<hr />
</div>
<div id="tailwinds-growth-prospects" class="section level6">
<h6>üöÄ <strong>2. Tailwinds &amp; Growth Prospects</strong></h6>
<div id="strong-revenue-earnings-momentum" class="section level9">
<p class="heading">‚úÖ <strong>1. Strong Revenue &amp; Earnings Momentum</strong></p>
<ul>
<li><strong>Quarterly Revenue (Operations):</strong>
<ul>
<li><strong>‚Çπ18,984.51 crores lacs</strong> (Q2 FY26) vs.¬†<strong>‚Çπ11,409.09 crores lacs</strong> (Q2 FY25): <strong>+66.4% YoY</strong>.</li>
</ul></li>
<li><strong>Profit After Tax (PAT):</strong>
<ul>
<li><strong>‚Çπ5,878.58 crores lacs</strong> (Q2 FY26) vs.¬†<strong>‚Çπ2,659.92 crores lacs</strong> (Q2 FY25): <strong>+121% YoY</strong>.</li>
</ul></li>
<li><strong>6M PAT: ‚Çπ11,010 crores lacs</strong> ‚Äî already <strong>138% of previous full-year</strong> profit (‚Çπ7,994 crores lacs FY25), indicating strong momentum.</li>
</ul>
</div>
<div id="main-board-listing-institutional-visibility" class="section level9">
<p class="heading">‚úÖ <strong>2. Main Board Listing &amp; Institutional Visibility</strong></p>
<ul>
<li>Migration from <strong>SME to Main Board (BSE/NSE)</strong> on <strong>11 August 2025</strong> enhances:
<ul>
<li>Liquidity</li>
<li>Analyst coverage</li>
<li>Investor confidence</li>
<li>Eligibility for indices and mutual funds</li>
</ul></li>
<li>Upcoming <strong>investor meet in Singapore (Dec 1-2, 2025)</strong> signals confidence in international outreach and access to global capital.</li>
</ul>
</div>
<div id="dual-growth-engines-with-clear-segmentation" class="section level9">
<p class="heading">‚úÖ <strong>3. Dual Growth Engines with Clear Segmentation</strong></p>
<p>JSLL has two distinct operating segments under <strong>Ind AS 108</strong>: 1. <strong>Ayurvedic Healthcare Services</strong>: <strong>‚Çπ9,392 crores lacs</strong> (Q2), stable QoQ. 2. <strong>Trading of Ayurvedic Products</strong>: High growth, <strong>‚Çπ9,592 crores lacs</strong> (Q2 FY26) vs.¬†<strong>‚Çπ5,005 crores lacs</strong> (Q2 FY25) ‚Äî <strong>+91.6% YoY</strong>.</p>
<blockquote>
<p><strong>Observation</strong>: The trading segment is the primary growth driver.</p>
</blockquote>
</div>
<div id="healthy-operating-cash-flow" class="section level9">
<p class="heading">‚úÖ <strong>4. Healthy Operating Cash Flow</strong></p>
<ul>
<li><strong>Net Operating Cash Flow (6M FY26): ‚Çπ13,746 crores lacs</strong>.</li>
<li>Slight increase in trade receivables but manageable.</li>
<li><strong>Cash balance up to ‚Çπ2,402 crores lacs</strong> (from ‚Çπ2,298 crores lacs), indicating strong liquidity.</li>
</ul>
</div>
<div id="strategic-expansion-new-subsidiary-capex" class="section level9">
<p class="heading">‚úÖ <strong>5. Strategic Expansion (New Subsidiary &amp; Capex)</strong></p>
<ul>
<li>Incorporation of <strong>Jeena Green Resources Pvt Ltd (JGRPL)</strong> in March 2025 indicates:
<ul>
<li>Expansion into <strong>ancillary sectors</strong> (possibly sustainable practices, green supply chain).</li>
<li>Though JGRPL is currently loss-making (‚Çπ3.57 crores lacs loss in Q2), it reflects <strong>long-term strategic investment</strong>.</li>
</ul></li>
<li>Capex of <strong>‚Çπ2,304 crores lacs</strong> (PPE + CWIP) shows <strong>capacity building</strong>.</li>
</ul>
</div>
<div id="strong-auditor-engagement-governance-improvements" class="section level9">
<p class="heading">‚úÖ <strong>6. Strong Auditor Engagement &amp; Governance Improvements</strong></p>
<ul>
<li>Appointment of <strong>M/s Deepak K Garg &amp; Associates</strong> as internal auditors adds oversight.</li>
<li>Engagement of <strong>KRA &amp; Co (past)</strong> and <strong>Walker Chandiok &amp; Co LLP (current)</strong> suggests professional auditing standards.</li>
<li>Reviewer reliance on predecessor auditors indicates <strong>clean handover</strong>.</li>
</ul>
</div>
<div id="share-split-dividend-payout" class="section level9">
<p class="heading">‚úÖ <strong>7. Share Split &amp; Dividend Payout</strong></p>
<ul>
<li>Equity <strong>split from ‚Çπ10 face value to ‚Çπ2</strong> in June 2025 allows:
<ul>
<li>Broader shareholder base</li>
<li>Improved stock affordability</li>
</ul></li>
<li>Dividend declared: <strong>‚Çπ1.10 per share (55% payout ratio)</strong> for FY25 ‚Üí signals <strong>confidence in earnings sustainability</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6>‚ö†Ô∏è <strong>3. Headwinds &amp; Challenges</strong></h6>
<div id="ind-as-transition-restatements" class="section level9">
<p class="heading">‚ùå <strong>1. Ind AS Transition &amp; Restatements</strong></p>
<ul>
<li><strong>First-time adoption of Ind AS</strong>: Effective April 1, 2024.</li>
<li><strong>Financials for FY24 &amp; Q2 FY25 have been restated</strong> under Ind AS, causing:
<ul>
<li><strong>Downward revision in profit</strong>: From <em>previous GAAP</em> FY25 PAT of <strong>‚Çπ9,072 crores lacs</strong> to <strong>‚Çπ7,994 crores lacs</strong> under Ind AS.</li>
<li><strong>Equity adjustment</strong>: Down by <strong>‚Çπ1,667 crores lacs</strong> due to lease recognition, credit loss provisioning, and deferred tax impacts.</li>
</ul></li>
<li><strong>Risk</strong>: Investors may view the restatement as earnings ‚Äúdeflation‚Äù and question historical performance.</li>
</ul>
</div>
<div id="high-other-expenses" class="section level9">
<p class="heading">‚ùå <strong>2. High Other Expenses</strong></p>
<ul>
<li><strong>Other Expenses (Q2): ‚Çπ4,053 crores lacs</strong>, down from ‚Çπ4,720 crores lacs (Q1), but still high.</li>
<li>For 6M: <strong>‚Çπ8,773 crores lacs</strong>, nearly <strong>24% of revenue</strong>.
<ul>
<li>Includes marketing, administrative, legal, logistics?</li>
<li>Not clearly itemized ‚Äî raises transparency concerns.</li>
</ul></li>
</ul>
</div>
<div id="jgrpl-subsidiary-is-eroding-consolidated-profits" class="section level9">
<p class="heading">‚ùå <strong>3. JGRPL Subsidiary is Eroding Consolidated Profits</strong></p>
<ul>
<li><strong>Loss of ‚Çπ3.57 crores lacs</strong> (Q2) and <strong>‚Çπ7.57 crores lacs</strong> (YTD) from new subsidiary.</li>
<li>Total income: ‚Çπ0.</li>
<li>Could drag results until scale.</li>
<li>Reviewed externally but <strong>not audited by current auditor</strong> ‚Äî adds small oversight risk.</li>
</ul>
</div>
<div id="high-finance-costs-leverage-risk" class="section level9">
<p class="heading">‚ùå <strong>4. High Finance Costs &amp; Leverage Risk</strong></p>
<ul>
<li><strong>Finance Cost: ‚Çπ434.6 crores lacs</strong> (Q2) ‚Äî up from ‚Çπ166 crores lacs (Q1).</li>
<li>Includes <strong>interest on lease liabilities (Ind AS 116)</strong>.</li>
<li><strong>Total Borrowings (Short + Long Term): ‚Çπ28 crores lacs (current) + ‚Çπ30.4 crores lacs (non-current)</strong>.</li>
<li>While debt is low, <strong>lease liabilities are high</strong>:
<ul>
<li><strong>Current Lease Liability: ‚Çπ2,472 crores lacs</strong>.</li>
<li><strong>Non-current: ‚Çπ8,088 crores lacs</strong>.</li>
</ul></li>
<li>Combined: <strong>‚Çπ10,561 crores lacs</strong>, a <strong>significant off-balance sheet obligation</strong>.</li>
</ul>
</div>
<div id="working-capital-pressure" class="section level9">
<p class="heading">‚ùå <strong>5. Working Capital Pressure</strong></p>
<ul>
<li><strong>Trade Receivables</strong>: Increased from ‚Çπ8,426 crores lacs ‚Üí ‚Çπ9,283 crores lacs (6M) ‚Äî <strong>+10%</strong> vs.¬†102% revenue growth.</li>
<li><strong>Inventories</strong>: From ‚Çπ1,154 crores lacs to ‚Çπ1,573 crores lacs ‚Äî inventory days may be increasing.</li>
<li><strong>Risk</strong>: Potential liquidity stress if receivables stretch or collections slow in future.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-strategy-outlook" class="section level6">
<h6>üìà <strong>4. Growth Prospects &amp; Strategy Outlook</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Area</strong></th>
<th><strong>Outlook</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue Growth</strong></td>
<td>Strong in <strong>product trading</strong>; services stable. Potential to scale product reach through e-commerce, partnerships.</td>
</tr>
<tr class="even">
<td><strong>Geographic Expansion</strong></td>
<td>Investor meet in <strong>Singapore</strong> suggests possible <strong>Southeast Asia expansion</strong>. Emerging markets receptive to Ayurveda.</td>
</tr>
<tr class="odd">
<td><strong>Digital &amp; Brand Building</strong></td>
<td>Company brands itself as ‚ÄúFreedom from 2D Diseases &amp; Drugs‚Äù ‚Äî strong narrative, but marketing spend efficiency needs monitoring.</td>
</tr>
<tr class="even">
<td><strong>Segment Margins</strong></td>
<td><strong>Trading EBIT margin:</strong> ~42% (‚Çπ4,054 / ‚Çπ9,592).<br><strong>Services EBIT margin:</strong> ~48% (‚Çπ4,537 / ‚Çπ9,392).<br>Strong, but declining due to other unallocated expenses.</td>
</tr>
<tr class="odd">
<td><strong>Scalability</strong></td>
<td>Infrastructure growth (PPE up 9% QoQ) supports scaling.</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Projected FY26 Revenue (6M run-rate): ~‚Çπ37,000 crores lacs</strong> ‚Üí could hit <strong>‚Çπ74,000 crores lacs annually</strong>. <strong>6M PAT: ‚Çπ11,010 crores lacs</strong> ‚Üí implies <strong>‚Çπ22,000+ crores lacs</strong> annualized profit.</p>
</blockquote>
<p>‚ö†Ô∏è <em>Caveat: Margins may compress on scaling; reinvestment needs are high.</em></p>
<hr />
</div>
<div id="key-risks-summary" class="section level6">
<h6>‚ö†Ô∏è <strong>5. Key Risks Summary</strong></h6>
<table>
<colgroup>
<col width="43%" />
<col width="26%" />
<col width="29%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Category</strong></th>
<th><strong>Detail</strong></th>
<th><strong>Severity</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Accounting &amp; Compliance Risk</strong></td>
<td>Ind AS restatements and adjustments may confuse investors. Need for consistent future disclosures.</td>
<td>High</td>
</tr>
<tr class="even">
<td><strong>Governance Risk</strong></td>
<td>Limited disclosures on ‚Äúother expenses‚Äù. Need more transparency post-main board listing.</td>
<td>Medium</td>
</tr>
<tr class="odd">
<td><strong>Leverage Risk</strong></td>
<td>High lease obligations (‚Çπ10,561 crores lacs) ‚Äî while finance costs are manageable now, interest rate hikes could impact.</td>
<td>Medium</td>
</tr>
<tr class="even">
<td><strong>Subsidiary Risk</strong></td>
<td>JGRPL is not contributing and may remain a drain. Integration risks possible.</td>
<td>Medium</td>
</tr>
<tr class="odd">
<td><strong>Working Capital Risk</strong></td>
<td>Rapid receivables growth may signal cash conversion lag. Needs monitoring.</td>
<td>Medium</td>
</tr>
<tr class="even">
<td><strong>Market Risk</strong></td>
<td>Ayurveda sector faces competition, regulatory scrutiny (AYUSH standards), counterfeit products.</td>
<td>Medium-High</td>
</tr>
<tr class="odd">
<td><strong>Valuation Risk</strong></td>
<td>If earnings scale but P/E is bid up prematurely, correction risk exists.</td>
<td>Medium</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="investor-takeaway-final-summary" class="section level6">
<h6>üí° <strong>6. Investor Takeaway &amp; Final Summary</strong></h6>
<div id="positives-tailwinds" class="section level9">
<p class="heading">‚úÖ <strong>Positives (Tailwinds)</strong></p>
<ul>
<li><strong>Explosive revenue and profit growth</strong> post-main board listing.</li>
<li>Dual business model with high-margin Ayurveda products and healthcare services.</li>
<li><strong>Strong cash generation</strong>, improving corporate governance.</li>
<li>Strategic expansion into new verticals via subsidiaries.</li>
<li>Proactive communication (investor meet notification), signaling transparency.</li>
</ul>
</div>
<div id="caution-areas-headwinds" class="section level9">
<p class="heading">‚ö†Ô∏è <strong>Caution Areas (Headwinds)</strong></p>
<ul>
<li><strong>Ind AS transition</strong> caused downward revisions in past earnings ‚Äî may deter conservative investors.</li>
<li><strong>High lease liabilities</strong> and growing receivables demand vigilance.</li>
<li><strong>Opacity in ‚Äúother expenses‚Äù</strong> and minimal R&amp;D spend could concern long-term scalability.</li>
<li>Subsidiary currently loss-making.</li>
</ul>
</div>
<div id="growth-outlook" class="section level9">
<p class="heading">üéØ <strong>Growth Outlook</strong></p>
<ul>
<li><strong>Short-Term (1-2 years)</strong>: Strong growth likely to continue; momentum in Ayurvedic product distribution.</li>
<li><strong>Mid-Term</strong>: Potential for international expansion (SE Asia), brand licensing, or franchise model scaling.</li>
<li><strong>Long-Term</strong>: Will depend on <strong>margin sustainability</strong>, innovation, brand strength, and operational transparency.</li>
</ul>
<hr />
</div>
</div>
<div id="conclusion-bullish-with-caution" class="section level6">
<h6>üèÅ <strong>Conclusion: Bullish with Caution</strong></h6>
<p><strong>Jeena Sikho Lifecare (JSLL)</strong> presents a <strong>high-growth investment opportunity in the Ayurvedic wellness sector</strong>, capitalizing on rising global interest in natural medicine.</p>
<p>‚úÖ <strong>Upside catalysts</strong>: - Sustained revenue growth - International investor engagement - High-margin business model - Healthy cash flow</p>
<p>‚ö†Ô∏è <strong>Downside risks</strong>: - Accounting transition noise - Margin pressures from operating expenses - Lease-heavy balance sheet - Dependency on product trade segment</p>
<blockquote>
<p><strong>Verdict</strong>: <strong>Hold/Buy on dips with long-term view</strong>, but <strong>monitor</strong> receivables, expenses, and future audit rigor. This is a <strong>high beta, high-growth story</strong> suited for investors with an <strong>appetite for emerging Ayurvedic champions</strong>.</p>
</blockquote>
<hr />
<p><strong>Key Metrics Snap (Q2 FY26):</strong> | Metric | Value (in ‚Çπ crores lacs) | |‚Äî‚Äî‚Äì|‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî-| | Revenue (Q2) | 19,129 | | PAT (Q2) | 5,879 | | EPS (Basic) | ‚Çπ4.73 | | Debt (Net) | ‚Çπ(1,030) ‚Üí Strong cash buffer | | ROE (6M) | ~42% (annualized) | | Payout Ratio (FY25) | 55% |</p>
<p>‚ÄîEnd of Analysis‚Äî</p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
